Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone

Abstract

Background: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. However, concern remains that pioglitazone may increase the risk for heart failure (HF) in susceptible individuals.

Methods: In IRIS, patients with insulin resistance but without diabetes mellitus were randomized to pioglitazone or placebo (1:1) within 180 days of an ischemic stroke or transient ischemic attack and followed for ≤5 years. To identify patients at higher HF risk with pioglitazone, we performed a secondary analysis of IRIS participants without HF history at entry. HF episodes were adjudicated by an external review, and treatment effects were analyzed using time-to-event methods. A baseline HF risk score was constructed from a Cox model estimated using stepwise selection. Baseline patient features (individually and summarized in risk score) and postrandomization events were examined as possible modifiers of the effect of pioglitazone. Net cardiovascular benefit was estimated for the composite of stroke, myocardial infarction, and hospitalized HF.

Results: Among 3851 patients, the mean age was 63 years, and 65% were male. The 5-year HF risk did not differ by treatment (4.1% pioglitazone, 4.2% placebo). Risk for hospitalized HF was low and not significantly greater in pioglitazone compared with placebo groups (2.9% versus 2.3%, P=0.36). Older age, atrial fibrillation, hypertension, obesity, edema, high C-reactive protein, and smoking were risk factors for HF. However, the effect of pioglitazone did not differ across levels of baseline HF risk (hazard ratio [95% CI] for pioglitazone versus placebo for patients at low, moderate, and high risk: 1.03 [0.61-1.73], 1.10 [0.56-2.15], and 1.08 [0.58-2.01]; interaction P value=0.98). HF risk was increased in patients with versus those without incident myocardial infarction in both groups (pioglitazone: 31.4% versus 2.7%; placebo: 25.7% versus 2.4%; P<0.0001). Edema, dyspnea, and weight gain in the trial did not predict HF hospitalization but led to more study drug dose reduction with a lower mean dose of pioglitazone versus placebo (29±17 mg versus 33±15 mg, P<0.0001). Pioglitazone reduced the composite outcome of stroke, myocardial infarction, or hospitalized HF (hazard ratio, 0.78; P=0.007).

Conclusions: In IRIS, with surveillance and dose adjustments, pioglitazone did not increase the risk of HF and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy.

Clinical trial registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00091949.

Keywords: heart failure; insulin resistance; pioglitazone; stroke; thiazolidinedione.

Figures

Figure 1. Time to First Heart Failure Event, Any Heart Failure (A), Hospitalized Heart Failure (B) and Non-hospitalized Heart Failure (C), by Treatment Group

(pioglitazone, solid line; placebo, dashed line)

Figure 2. Heart Failure by Baseline Risk and Treatment Group

*Score: Age 80+ (4 points); age 65–79 (2 points); atrial fibrillation (2 points); hypertension history, current smoker, BMI ≥30 kg/m2, leg edema, C-reactive protein>3.0 mg/dL (1 point).

Figure 3. Heart Failure (A) and Time to Heart Failure (B) by MI Status during follow-up and Treatment Group

(Heart failure occurring on or after date of MI for patients with MI, or at any time during follow-up for patients without MI; A. hospitalized, solid; non-hospitalized, shaded; B. patients with MI, black lines; patients without MI, grey lines; pioglitazone, solid lines; placebo, dashed lines)

Figure 4. Distribution of Study Drug Dose in Year 1 for Patients without Heart Failure during Follow-up, for Placebo Group (A) and Pioglitazone Group (B)

(off drug, dark grey; 15 mg, medium grey; 30 mg, light grey; 45 mg, very light grey)

Figure 5. 5-Year Risk for Outcomes by Treatment Group

(placebo [n=1928], shaded; pioglitazone [n=1923], solid; ARD=absolute risk difference; CI=confidence interval)